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Introduction
Johnson and Johnson ($JNJ) is a Multinational Corporation that was founded in 1886. It
currently operates in the medical devices, pharmaceuticals, and consumer packaged goods
industries. The company is a part of the DOW jones industrial average. The corporation has over
250 subsidiaries and brands that serve to improve everyday life through their products. JNJ’s credo
is “ We believe our first responsibility is to the doctors, nurses and patients, to mothers and fathers
and all others who use our products and services” as well as stating “ We are responsible for our
employees, the men and women who work with us throughout the world”, “Responsible to our
communities in which we live and work”, and “ Our final responsibility is to our stockholders.
Businesses must make a sound profit. We must experiment with new ideas. Research must be
carried on, innovative programs developed, and mistakes paid for”.
[Source: Credo]
This research paper will aim to analyze the effects of a volatile administration’s decisions
as well as current economic conditions on a well diversified mature company such as Johnson and
Johnson. Factors such as the historical bull economy, rising interest rates, trade war scares are key
intrinsic factors to look at when analyzing a company in 2018.

Company Description
Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson started the
company in New Jersey, USA in 1886. One of the first products that the company offered were
ready to use surgical dressings and the first commercial first aid kits. They were initially designed
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to help the rail road workers laying the foundation of the expansion to the west. However, soon
the ready to use surgical dressings and the first aids kits became the standard practice in treatment
of injuries throughout the USA. About a decade later, Johnson and Johnson launched its widely
known maternity products such as the Johnson’s Baby Powder. The company radically expanded
its line of products in the upcoming years revolutionizing women’s health with the mass
production of sanitary protection products. JNJ’s subsidiaries had extremely high growth in the
mid-20th century. Ethicon, a manufacturer of surgical sutures and wound closure devices
dominated the market as a result of World War 2, while newly acquired McNeil Laboratories and
Cilag Chemie expanded JNJ’s presence in the pharmaceutical business. McNeil Laboratories
created the first prescription aspirin pain reliever, Tylenol.
Soon afterwards, Johnson and Johnson acquired Janssen Pharmaceutica of Belgium in
1961. Janssen’s founder Dr. Paul Janssen was widely recognized as the most prolific figure in the
pharmaceutical industry in the 20th century. Johnson and Johnson’s acquire of Janssen
Pharmaceutica has been its gold rush since the 20th century that will be analyzed in a later section.
Johnson and Johnson continued its rapid growth in the late 20th century by pioneering into
numerous business areas listed below.







Vision Care
Mechanical Wound Closure
Diabetes Management
Minimally invasive surgery
Cardiology/ Coronary Stent/ Drug Stent
Beginning of operations in China and Egypt
[Source: History of Johnson and Johnson]
The company’s growth in the 21st century can be described in two words: Acquisition and

Innovation. Johnson and Johnson have been growing its business through large notable
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acquisitions. Acquisitions such as Tibotec-Virco to increase its pharmaceutical reach into the areas
of HIV/AIDS, Vogue International to boost business in vision area, and Pfizer Consumer
Healthcare to increase foothold in the consumer area have all been very successful for Johnson
and Johnson. As of today, Johnson and Johnson have a market cap of $341.3 Billion, while
reporting worldwide sales of $78.7Billion in 2017. It currently has 134,000 employees with
operation in 57 countries and products sold in 197 countries.
[Source: Forbes]

Leadership Team
JNJ’s leadership team is comprised of experienced and diversified individuals who have been
with the company for long periods of time. They are headed by Alex Gorsky, who was appointed
CEO and Chairman of the Board of Directors in 2012.
Key Leadership Figures
Alex Gorsky
Chairman of the Board of
Directors & CEO

Joaquin Duato
Vice Chairman of the Executive
Committee, Consumer

Joseph J. Wolk
Executive VP, CFO

Ashley McEvoy
Executive VP, Medical Devices

Background
Alex Gorsky is a U.S Army Captain who acquired a BS degree from
U.S Military Academy at Westport. Alex started his journey at
Johnson and Johnson in 1988 when he became a sales
representative with Janssen Pharmaceutica, one of Johnson and
Johnson’s subsidiaries. He rose throughout the ranks to become
the 7th person to serve as CEO and Chairman of Johnson and
Johnson in 2012.
Joaquin holds an MBA degree from ESADE Business School in Spain
as well as a Master of International Management degree from
Thunderbird in Arizona, USA. Joaquin has been working at JNJ for
28 years while being responsible for areas such as Supply Chain, IT,
Global Services and his latest responsibility being responsible for
the Pharmaceuticals and Consumer Sectors of JNJ.
Joseph J. Wolk is a certified CPA with a BS degree in Finance from
St. Joseph’s University. Like many other leadership figures, Joseph
has been with the company for over 20 years serving in key
business areas. Joseph J. Wolk is currently responsible for financial
and investor relations activities.
Ashley has been with JNJ for more than 20 years while being
responsible for areas such as Consumer & Medical Devices.
Currently, Ashley leads the surgery, orthopedics, interventional
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Jennifer Taubert
Executive VP, Pharmaceuticals

Paul Stoffels, M.D
Chief Scientific Officer

solutions and eye health businesses which generate $27Billion in
revenue. Credited with leading the successful acquisition of Pfizer
Consumer healthcare.
Jennifer Taubert received a Bachelors Degree in Pharmacology
from the UC Santa Barbara as well as a MBA from UC Los Angeles.
Jennifer joined JNJ in 2005 to lead the global strategy for Internal
Medicine. She has quickly risen through the ranks to become the
leader of Pharmaceutical division of JNJ. Under Jennifer’s
leadership, the Pharmaceutical division has become the driving
force behind JNJ’s growth.
Since joining JNJ in 2002, Stoffels has been responsible for R&D
leadership roles as well as spearheading the research and product
aspects of all companies that JNJ operate. Paul Stoffels was a CEO
of Virco and Chairman of Tibotec which were breakthrough
companies in the treatment of HIV.

Strengths

Weakness



Operates in Industries that will last as



Legal Troubles

long as humans walk the earth



Changing Cultural Views towards



Strong Leadership Team



Well Diversified Businesses



Globally known Brand Name



Large Customer Base

Opportunities


Consolidation of Industries



Rapid technological advancement
Rates to help medical devices industry



Unending opportunities in
pharmaceutical industry

pharmaceuticals

Threats


Cultural shift away from Brand
companies



Cultural shift in views towards large
Corporations
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Cultural shift in views towards
production ingredients/methods.
[Source: Leaderhsip Team]

Industry Analysis
Top business Segments

% of Total Revenue

Pharmaceuticals

44.67%

Medical Device & Diagnostics

35.75%

Nutritionals

5.48%

Skin Care

5.03%

Other

9.08%
Johnson and Johnson’s well diversified business approach means that multiple industries

must be analyzed. It currently possesses large market shares in Consumer healthcare products,
pharmaceuticals, and medical devices & diagnostics. The graph above shows JNJ’s business
segments as percentage of Revenue

Pharmaceuticals
The infrastructure of American medicine allows pharmaceutical companies very distinct
advantages if they are willing to go through the massive capital-intensive risk of developing new
drugs. However, the high risk comes with high reward as the patent protection allows for years of
large profits due to absence of competition. This is reflected in the graph as the pharmaceutical
segment makes up almost half of total revenues.

Johnson and Johnson has numerous

pharmaceutical products specializing in profitable areas such as Immunology, Cardiovascular &
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Metabolic Disease, and Pulmonary Hypertension due to the high cost of these drugs. Johnson and
Johnson’s pharmaceutical business is driven by Janssen Pharmaceutica, who has been the driving
force behind its growth. Johnson and Johnson is expected to announce 10 new product fillings
with the FDA for approval over the next four years which could have large positive implications
on future profits. This coupled with the expectation of global pharma market to grow by 4.5%
annually is a very positive sign for Johnson and Johnsons leading industry sector.
[Source: Pharmaphorum]

Medical Device & Diagnostics
The medical device and diagnostics segment is made up from devices used all around the
world in hospitals, laboratories, and other healthcare related locations. As with Pharmaceuticals,
the Research and development phase of these products are the most capital and resource intensive
parts of the product life cycle. However, it too can benefit from prolonged product usefulness as it
takes extremely long time to be replaced by newer/ improved devices. Johnson and Johnson’s
second largest business have been experiencing global growth of 6.0%. It’s driving forces were
16.4% growth in electrophysiology devices, 11.2% growth in vision sales, and 5.5% growth in
surgical equipment.
[Source: Medical Devices]

Consumer
The consumer segment is perhaps the segment that Johnson and Johnson is most known
for. From its child care products to the band-aids that everyone uses, the company’s over the
counter healthcare and pharmaceutical supplies have become a stable in any westernized country
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in the world. However, this segment is the most competitive segment that Johnson and Johnson
operates in. As a result, consumer goods such as nutritionals, skin care, and other consumer
products only make up about 1/5th of the total revenue. The Consumer Products industry does not
have high requirements for new entries. Johnson and Johnson and other large corporations are
experiencing strong competition from private labels leading to deteriorating revenues. Thus,
Author Trefis Team of Forbes estimates growth in the consumer products industry to be in the low
single digits.
[Source:Forbes]

Top Competitors
Pfizer Inc, Merck &Co, Inc, and Procter and Gamble Co are the three largest competitors
of Johnson and Johnson. Basic financial overview is shown below in millions of dollars for the
past year.
Market Cap

Revenue

Net Income

Johnson and Johnson

$379,594

$80,684

$1,372

Pfizer Inc

$255,698

$53,348

$23,290

Procter and Gamble

$225,808

$65,059

$15,411

Merck & Co

$189,612

41,260

$1,368

Growth Rate
Industry growth is the second biggest thing to look at when analyzing a company. If a
company is in a dying industry, it does not matter how good the company is doing. If the end
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horizon is set, then the investment horizon is set. As a result, an efficient market should reflect that
in the company’s stock price. The growth rate of the pharmaceuticals industry is absurd. The below
graph shows the Revenue of the Worldwide Pharmaceutical Market in the last 15 years in billions
of dollars. (Statista) Putting these figures into excel gives us a compounded annual growth rate of
around 7% over the last 15 years.

Johnson & Johnson’s year over year ending with the second quarter of this year was 11.24%.
Whereas the pharmaceutical industry growth was 5.88% while the healthcare sector was at a 4.3%
growth.

Porter Analysis
Pharmaceuticals & Medical Devices
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The porter analysis of the pharmaceutical and medical devices industry is very similar. The
threat of substation is very low because of the patents that are rewarded. The threat of new entry
is also very low as it requires immense amount of capital and large amounts of resources to
research and develop new drugs and devices.
The supplier power is very low as a company that is Johnson and Johnson’s size has large
bargaining power due to their size and high number of suppliers available. The buyer also does not
have large amount of bargaining power as there tends to be few substitutes for a necessary
drug/device as well as the cost of changing drugs could be a life-threatening choice. The immense
reward for researching and developing these drugs/devices tend to lead to high competition among
companies with billions of dollars being pumped into R&D.

Consumer
Over the counter medicines, basic healthcare supplies, nutritionals, and skin care are all
products that are heavily competitive. As a result, the porter analysis for this industry is the
opposite of the previous analysis. The only similar factor is the supplier power. The supplier still

Togtokhsuren 12

does not hold a lot of power against these large companies due to competition and scale. However,
the threat of substitution is very high as the threat of new entry looms. Getting into healthcare
consumer goods is not as capital intensive as other markets. The buyer holds immense power as
the cost of changing between products is almost non-existent and price sensitivity is extreme.

Macro-Economic Analysis
Various economic indicators were used to analyze the current state and future of the
macroeconomy. Each indicator has their strengths and weaknesses. For example, Growth in Gross
Domestic Product is a very good indicator of how the health of the economy has been, whereas
stock prices are a good leading indicator.

Lagging Indicators
One of the bread and butter indicators of economic analysis is the GDP Growth. Professor
Mishkin from Columbia University states that “Gross Domestic Product is such a broad measure
of aggregate economic activity that it is sometimes viewed as a proxy for the business cycle itself”
(Mishkin 211). As a result, I have extracted quarterly GDP growth over the past 10 years and
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compared it with Quarterly Corporate growth data from the statistics created by the Federal
Reserve Bank of Saint Louis.

(Corporate Profits After Tax vs GDP)
As we can see from the above example, Quarterly Corporate Growth has been hand in hand
with the Quarterly GDP Growth of the past ten years leading us into the longest bull market of
modern history. The next indicator that is used in our analysis is percent change in consumer prices
provided by FRED. Inflation tends to rise during expansions of the economy and fall during
contractions. As a result, inflation is a very procyclical indicator of the economy. However,
Inflation tends to linger on after a change in the macro-economy. Thus, it is categorized as a
lagging indicator.
Currently, the consumer price index for United States is sitting at 2.88% as of July 2018.
It is currently at its highest point since 2012. This fact can be used to indicate that the economic
cycle could be reaching its peak soon.
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(Inflation, U.S.A)

Coincidental Indicators
The Coincidental indicators that are used in this macroeconomic analysis are Personal
Consumption Expenditure and Gross Domestic Investment. When the economy is at a good health,
the aggregate economy tends to spend and save more. Both actions go down during contractions
of the economy. Based on the graph below, it is proven again that we are in one of the longest
lasting bull market/ expanding economy of the past century.

(Gross Private Domestic Investment, USA)
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(Personal Consumption Expenditures, USA)

Leading Indicators
The leading indicator used in this macro-economic analysis is the S&P 500 Index.
Professor Mishkin states that financial assets tend to move with the business cycle and that stock
markets tend to top out before the business cycle’s peak and begin to rise before the economy
emerges from a recession.

(Growth of S&P 500)

Forecast of the Economy
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The short-term forecast (<1 year) of the economy looks bright based on these indicators.
Our leading indicator S&P500 makes it hard for us to judge when the stock market will top off
signaling an incoming recession.
The medium-term (1-5 years) forecast of the economy is that a recession is undoubtedly
coming. It is hard to judge if it will happen within a medium term or a long term. However, it is
safe to assume that it is on the horizon based off the fact that we have been experiencing all-time
highs in stock prices, personal consumption expenditures, and gross private domestic investment.
Also, the current political factors such as the ongoing trade wars will only hasten the next
recession. Based on history, there are no winners in a trade war.
The long-term forecast (5 years <) of the economy is that the economy will face a
recession soon, but it will recover from it within a short period of time. The Fed has been doing a
remarkable job of conducting its monetary policies so that it balances the fiscal policies of our
government. That will only be challenged as the volatile decisions of the current administration
continues.

Financial Ratio Analysis (See Appendix for Spreadsheet)
Johnson and Johnson’s annual reports have been very strong up until 2017. This was
mainly due to the new tax law that was passed in the early 2017. JNJ reported a $13.6 billion
charge to bring back cash that was accumulated on foreign soil. (Erman) This was done so that
they could bring back those earnings to fund U.S operations by increasing R&D, dividends, and
decreasing debt. This makes the financial statements look odd but is a very strong financial move
by the company.
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Financial Ratio Analysis
ROE
ROA
Net Profit Margin
Total Asset Turnover
Equity Multiplier

2013
18.68%
10.42%
19.40%
0.54
1.79

2014
23.40%
12.45%
21.96%
0.57
1.88

2015
21.66%
11.55%
21.99%
0.53
1.88

2016
23.49%
11.71%
23.01%
0.51
2.01

2017
2.16%
0.83%
1.70%
0.49
2.61

Current Ratio
Quick Ratio
Payables Turnover
Fixed Asset Turnover

2.20
1.89
3.57
0.83

2.36
2.04
2.98
1.01

2.17
1.88
3.23
0.97

2.47
2.16
3.13
1.04

1.41
1.12
3.47
0.08

Debt Ratio
Long Term Debt/ Total Asset
Interest Coverage

44.2%
10.0%
41.61

46.8%
11.5%
46.89

46.7%
9.6%
42.56

50.1%
15.9%
33.45

61.8%
19.5%
25.96

The key ratios that was first focused on were the Return on Equity and the Return on Asset.
Return on Equity measures the company’s profitability given the amount of money invested
whereas ROA measures how well the company is using its assets to fuel earnings. The ROE has
been hovering around 18%-24% mark indicating very good returns on investment. The ROA
ranging from 10.42% to 12.45% is showing that the company is doing decently on managing its
assets to generate earnings. However, both the ratios took a nose dive in 2017. This is mainly due
to the huge 13.6$ billion income tax reducing net income to $1.3 billion. As a result, the difference
between the financial ratios for 2016 to 2017 should not be given a heavy weight.
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Du Pont
25.00%

3.00

20.00%

2.50
2.00

15.00%

1.50
10.00%

1.00

5.00%

0.50

0.00%

0.00
2013

2014

2015

Total Asset Turnover

Equity Multiplier

ROA

Net Profit Margin

2016

2017
ROE

The liquidity ratios of JNJ have been stable and solid until 2017. However, the decreased
amount of current assets available in 2017 dropped the liquidity of JNJ. This is a result of the
amount of cash that the company had to use to pay for the cost of bringing the oversea money back
into the U.S.

Liquidity Ratios
3.57
2.98
2.20
1.89

2.36
2.04

3.23

2.17
1.88

3.47
3.13
2.47
2.16
1.41
1.12

2013

2014
Current Ratio

2015
Quick Ratio

2016

2017

Payables Turnover
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The newly passed tax law and the decision to bring in the oversea money is coming at a good time.
JNJ’s debt has been rising through the last few years. The debt ratio is at a comparatively high
figure of 61.8% compared to 44.2% from just 5 years ago. The company has become more
leveraged on debt. This can also be seen in the LT Debt to total asset ratio. It has almost doubled
from 10% in 2013 to 19.5% in 2017. As a result of increased debt, the interest coverage ratio has
also decreased substantially from 41.61% to 25.96%.
When comparing JNJ to its industry, few things jump out. Most of its ratios indicates what
we already know. JNJ is an established company well into its maturity stage in its business cycle.
Industry Comparison Q2 2018
Industry
JNJ
Avg
Y/Y Revenue Growth
TAT

10.27%
0.52

23.26%
0.4

Profitability
Gross Margin
Net Profit Margin

66.75
18.98%

67.8
11.95%

Liquidity
Quick Ratio
Interest Coverage

0.97
27.44

0.93
13.71

Year over year growth is half of the industry average. This is almost certainly due to JNJ’s
competitors being in the development/growth stage. A growth percent of 10.27% is also a
respectable number that can be attributed to the numerous mergers and acquisitions the company
has been carrying out. This is a commonly seen tactic for gigantic, mature companies to
supplement their growth.
Total Asset Turnover and Net Profit Margin also reveals that JNJ is more efficient at generating
revenue with its asset than its competitors. This efficiency can be attributed to its economy of
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scale and matured business processes whereas the large net profit margin could be attributed to
the patented business of pharmaceutical manufacturing. In Conclusion, the financial ratios of JNJ
reveal a mature and stable company that has carried out a large financial decision in 2017 for
long term profits.

External Financing Needed (See Appendix for Spread Sheet)
Johnson and Johnson had a unique 2017 that could skew forecast as a result of their tax
payment for bringing in oversea money to the U.S. As a result, 2017 was not included when
calculating averages.
Averages and CAGR from 2013-2016 were used to forecast pro-forma financial statements for
2018-2019. (2017xCAGR=2018 etc.)
Johnson and Johnson had a retention rate of about 87% from 2013-2016. The average net margin
from years 2013-2016 were 22%. Assuming that these two metrics do not change, External
Financing Needed for a 1.4% growth was -$12635 meaning that JNJ does not need external
financing to increase sales by its average growth rate of 1.4%. This is largely due to their large
net margin of 22%.
Retention Ratio
Net Margin
Growth rate
Current Sales 17'
Change in Sales
Next Year's Expected
Sales
Asset/Sales
Increase in Assets
Increase in Internal
Equity
EFN

87%
22%
1.40%
76450
1070
77520
206%
2202
14837
-12635
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Stock Valuation
The two stock valuation methods that were used to value JNJ stock were the Dividend
Discount Model and the Discounted Cash Flow Model. Johnson and Johnson is one of the best
dividend paying stocks on the market. This can be seen by its recent history of dividend payout
below. As a result, the Dividend Discount Model Calculations were very straight forward.
2012

Dividends Per share
Dividend Growth Rate
AVG Dividend Growth Rate

$

CAPM MODEL
1 year T-Bill % (10/5/2018)
JNJ Beta (3 year)
S&P 500 Index 10 year avg
Expected Return

0.61 $

2013

2014

2015

2016

2017

2018

0.66 $ 0.70 $ 0.75 $ 0.80 $ 0.84 $ 0.90
8.20%
6.06%
7.14%
6.67%
5.00%
7.14% $
6.70%

2019 Estimated
0.96

2.644%
0.53
12.52%
7.878%

First step was to find the expected return using the CAPM Model. A one-year T-bill was
used as the risk-free rate while the 10-year average return for S&P 500 Index was used as the
expected market return. The dividend for 2019 was estimated using the average dividend growth
rate for the past 6 years. As a result, the price per share using the Dividend Discount Model came
out to $81.61 which is severely less than the current stock price of $139.10.
Price Per Share Using DDM Current Stock Price
$
81.61 $
139.10

The second method of stock valuation was the Discounted Cash Flow Method. The first
step was to find the WACC for JNJ. The coupon rate for a long-term bond issued by JNJ was

Togtokhsuren 22

used as the cost of debt. The CAPM model used in the DDM model provided the cost of equity.
The market value of equity was calculated using statistics as of 10/05/2018.
MV of Equity (10/05/2018)
Shares outstanding
2682756000
Share Price
139.1
MV of Equity
$373,171,359,600

The market value of debt was calculated using total debt as one big coupon bond with the
coupon payment being equal to the interest expenses. JNJ had a total of $ 345,810 Million of
total debt with an interest expense of $934 million. All outstanding bonds were used to calculate
the weighted average maturity of all outstanding debt. The average effective tax rate for years
2014-2017 were used as the corporate tax rate.
WACC Calculation
MV of Debt
Total Debt
$
Interest Expense
$
Weighted average maturity
Cost of Debt
MV of Debt
$

Cost of Equity
345,810,000,000
934,000,000
12.02
5.50%
189,759,233,112

0.0787828

Cost of debt

0.055

Weight of Equity

66.3%

Weight of Debt

33.7%

Corporate Tax Rate

16.9%

WACC

6.76%

The second step in the DCF method was estimating the FCF for the next three years. The
average growth rate from 2013-2017 were used as the basis for 2018-2020.

$

2013
2014
2015
13,553 $ 14,458 $ 15,713 $
6.26%
7.99%
6.11%

2016
15,418 $
-1.91%

2017
17,543
12.11%

2018

e
at
tim
Es

Free Cash Flow
Growth
Average +/- in Cash Flow

$

18,615

2019
$

19,753

2020
$

20,960

Togtokhsuren 23

The cash flows and the terminal value discounted at the rate of WACC equaled a PV of
$2,852,915 million dollars. Afterwards the PV was divided by shares outstanding to reveal a
price per share of $106.34 using the DCF method.
In Conclusion, both valuation methods revealed that the current stock price was overvalued
compared to its price estimated by fundamental analysis.

Notable Events
The biggest recent news regarding Johnson and Johnson was when a St. Louis Jury
awarded $4.69 billion in settlement to 22 women who claimed that Johnson and Johnson baby
powders caused ovarian cancer. (Bever) Also, The Department of Justice has announced that it
will support investigations and lawsuits against Johnson and Johnson and other companies in
relations to the opioids epidemic in the U.S.A. However, these news had minimal impact on
stock as it currently trades around $139.
[Source:DOJ Lawsuit]

Investment Recommendation
The conclusions derived from the different segments of this research would be the
following:

0
Strong
Sell

2.5
Weak
Sell

5
Hold

7.5
Weak
Buy

10
Strong
Buy

Criteria

Recommendation

Score out of 10

Company Leadership

Strong Buy

10/10

Industry Analysis

Weak Buy

7.5/10
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Macroeconomic Analysis

Hold

5/10

Financial Ratios

Hold

5/10

Stock Valuation

Weak Sell

2.5/10

Overall (calculated by avg score)

Weak Buy

6/10



Strong leadership team with vast experience and large diversification



Very promising pharmaceutical/medical devices industry balanced by declining
consumer products division.



Macroeconomic Analysis is a “hold” due to the combination of the scary bull market/
current administration.



The hold recommendation the financial ratio segment is due to the unknown effect the
large transaction of 2017 will have on the future years.



The weak sell recommendation of the stock valuation is due the stock being overvalued
when analyzed in traditional methods. However, intrinsic values and the bull market
contribute to the over valuation of the stock.

In Conclusion, I believe that Johnson and Johnson is an above optimal buy for a semi
conservative investor with heavy emphasis on dividend payout.

Appendix
Excel sheets submitted separately with respective sections divided by the sheets in the workbook.
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